Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial
Digestion · 2024
DOI: 10.1159/000540527 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Digestion, 2024. Verfasst von Ryoji Ichijima und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine Nihon University School of Medicine, Tokyo, Japan, ryoji0331@yahoo.co.jp. Hauptthemen laut MEDLINE: Colonoscopy, Hypnotics and Sedatives, Benzodiazepines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
We conducted an investigator-initiated clinical trial in which remimazolam was used to achieve sedation in patients undergoing colonoscopies.
Methods
This multicenter, double-blind, placebo-controlled, phase III investigator-initiated trial included patients who underwent colonoscopy under sedation with remimazolam (initial dose: 3 mg; additional dose: 1 mg) or normal saline (placebo). The primary endpoint of the study was the successful sedation rate during colonoscopy, defined as achieving a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of ≤4 before the procedure, maintaining this score throughout colonoscopy, and requiring no more than five additional drug doses per 15 min.
Results
The sedation success rate was 95.0% (38/40 patients) in the remimazolam group and 0.0% (0/11 patients) in the placebo group (p < 0.01). The time from the end of procedure to regaining consciousness was 0.0 (interquartile range: 0.0–0.0) min in both groups. The time from the end of the procedure to ambulation was 5.0 (interquartile range: 0.0–10.0) min in the remimazolam group and 0.0 (interquartile range: 0.0–0.0) min in the placebo group (p = 0.02). Serious adverse events were not observed.
Conclusion
The use of remimazolam to achieve sedation in Japanese patients undergoing colonoscopy was more effective than placebo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine Nihon University School of Medicine, Tokyo, Japan, ryoji0331@yahoo.co.jp.
- Department of Gastroenterology, Kiriyama Clinic, Takasaki, Japan, ryoji0331@yahoo.co.jp.
- Division of Gastroenterology and Hepatology, Department of Medicine Nihon University School of Medicine, Tokyo, Japan.
- Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
- Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Gastroenterology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan.
Zitieren
APA
Ichijima, R., Ikehara, H., Ono, H., Hotta, K., Yamaguchi, D., Esaki, M., Minoda, Y., Nagata, Y., Ogura, K., Kiriyama, S., Sumiyoshi, T., & Kanmura, Y. (2024). Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial. Digestion. https://doi.org/10.1159/000540527
Vancouver
Ichijima R, Ikehara H, Ono H, Hotta K, Yamaguchi D, Esaki M, et al. Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial. Digestion. 2024. doi:10.1159/000540527
BibTeX
@article{Ichijima2024,
author = {Ichijima, Ryoji and Ikehara, Hisatomo and Ono, Hiroyuki and Hotta, Kinichi and Yamaguchi, Daisuke and Esaki, Mitsuru and Minoda, Yosuke and Nagata, Yasuhiko and Ogura, Kanako and Kiriyama, Shinsuke and Sumiyoshi, Tetsuya and Kanmura, Yuichi},
title = {Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial},
journal = {Digestion},
year = {2024},
doi = {10.1159/000540527}
}
EUVIMED